Professor Gareth Evans has established a national and international reputation in clinical and research aspects of cancer genetics, particularly in neurofibromatosis and breast cancer. He has developed a clinical service for cancer genetics in the North West Region of England, which is nationally regarded. He is an important opinion leader nationally through membership of committees and was chairman of the NICE Familial Breast Cancer Guideline Development Group (2002-2010) and is now clinical lead (2011-). He lectures throughout the UK and internationally on hereditary breast cancer and cancer syndromes. 

Prof Evans has published 1046 peer reviewed research publications; 352 as first or senior author. He has published over 150 reviews and chapters and has had a book published by Oxford University Press on familial cancer. He has an ISI web of knowledge H-index of 131 and google scholar of 173 having only published his first article in 1990. In the last 8 years he has raised over £55 million in grants for multicentre and local studies – approximately £45 million to Manchester. He is Chief Investigator on two NIHR program grants (2009-2014-£1.59 million) (2017-2020-£1million) on breast cancer risk prediction and also has an NIHR RfPB grant as CI (2011). He has led a successful bid for a nationally funded NF2 service (£7.5 million pa) that started in 2010 and is involved in the national complex NF1 service. He is overall cancer lead (3 themes) and Cancer Prevention Early Detection theme lead on the successful all Manchester NIHR Biomedical research centre bid (2017-2022-£28.5million). He is lead clinician on the NICE familial breast cancer guideline group and until recently a trustee of Breast Cancer Now and the Neuro Foundation. He is on the editorial board of JNCI and is a board member of the Science Strategy Committee of Breast Cancer Now. He was elected a fellow of the learned Society of Wales (FLSW) in 2020 and FRCOG ad eundem in 2021.